Therefore, CPVL-expressing TAMs may unleash anti-tumor effects by inhibiting SPP1-CD44 and promoting CXCL9-CXCR3 and C3-C3AR1 ligand-receptor reciprocal effects with other cells, like monocytes, neutrophils, and T cells. The gene discussed is CD44; the disease is neoplasm.